Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 Nov;98(2):178–184. doi: 10.1111/j.1365-2249.1994.tb06122.x

HIV-1 recombinant gp160 vaccine given in accelerated dose schedules

G J Gorse, D H Schwartz, B S Graham, T J Matthews, D M Stablein, S E Frey, R B Belshe, M L Clements, P F Wright, M Eibl, P E Fast
PMCID: PMC1534411  PMID: 7955519

Abstract

The purpose of this randomized, double-blind study was to test the safety and immunogenicity of an HIV-1LAI recombinant gp160 (rgp160) vaccine in healthy, uninfected volunteers using accelerated dosing schedules. Thirty volunteers were randomly assigned to receive 50-μg doses of rgp160 in one of two immunization schedules. Group 1 received rgp160 at times 0, 1, 2 and 5 months; and group 2 received rgp160 at times 0, 1, 2, 3 and 4 months. The vaccine was safe and stimulated high levels of HIV-1 envelope-specific binding antibody and T cell memory. There was a trend (P < 0.10) suggesting neutralizing antibodies were better induced by the regimen incorporating a rest period before the final immunization in group 1 volunteers. Both accelerated immunization schedules induced immune responses at levels similar to or better than those achieved by four rgp160 vaccine injections given over 12-18 months in other studies.

Full text

PDF
178

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson K. P., Lucas C., Hanson C. V., Londe H. F., Izu A., Gregory T., Ammann A., Berman P. W., Eichberg J. W. Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1. J Infect Dis. 1989 Dec;160(6):960–969. doi: 10.1093/infdis/160.6.960. [DOI] [PubMed] [Google Scholar]
  2. Barrett N., Eder G., Dorner F. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees. Biotechnol Ther. 1991;2(1-2):91–106. [PubMed] [Google Scholar]
  3. Barrett N., Mitterer A., Mundt W., Eibl J., Eibl M., Gallo R. C., Moss B., Dorner F. Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS Res Hum Retroviruses. 1989 Apr;5(2):159–171. doi: 10.1089/aid.1989.5.159. [DOI] [PubMed] [Google Scholar]
  4. Belshe R. B., Clements M. L., Dolin R., Graham B. S., McElrath J., Gorse G. J., Schwartz D., Keefer M. C., Wright P., Corey L. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. J Infect Dis. 1993 Dec;168(6):1387–1395. doi: 10.1093/infdis/168.6.1387. [DOI] [PubMed] [Google Scholar]
  5. Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990 Jun 14;345(6276):622–625. doi: 10.1038/345622a0. [DOI] [PubMed] [Google Scholar]
  6. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  7. Dolin R., Graham B. S., Greenberg S. B., Tacket C. O., Belshe R. B., Midthun K., Clements M. L., Gorse G. J., Horgan B. W., Atmar R. L. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med. 1991 Jan 15;114(2):119–127. doi: 10.7326/0003-4819-114-2-119. [DOI] [PubMed] [Google Scholar]
  8. Emini E. A., Schleif W. A., Nunberg J. H., Conley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 1992 Feb 20;355(6362):728–730. doi: 10.1038/355728a0. [DOI] [PubMed] [Google Scholar]
  9. FECSIK A. I., BUTLER W. T., COONS A. H. STUDIES ON ANTIBODY PRODUCTION. XI. VARIATION IN THE SECONDARY RESPONSE AS A FUNCTION OF THE LENGTH OF THE INTERVAL BETWEEN TWO ANTIGENIC STIMULI. J Exp Med. 1964 Dec 1;120:1041–1049. doi: 10.1084/jem.120.6.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fultz P. N., Nara P., Barre-Sinoussi F., Chaput A., Greenberg M. L., Muchmore E., Kieny M. P., Girard M. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science. 1992 Jun 19;256(5064):1687–1690. doi: 10.1126/science.256.5064.1687. [DOI] [PubMed] [Google Scholar]
  11. Gorse G. J., Belshe R. B. Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses. Scand J Infect Dis. 1991;23(1):7–17. doi: 10.3109/00365549109023368. [DOI] [PubMed] [Google Scholar]
  12. Gorse G. J., Belshe R. B., Newman F. K., Frey S. E. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network. Vaccine. 1992;10(6):383–388. doi: 10.1016/0264-410x(92)90068-u. [DOI] [PubMed] [Google Scholar]
  13. Gorse G. J., Frey S. E., Newman F. K., Belshe R. B. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network. J Clin Microbiol. 1992 Oct;30(10):2606–2612. doi: 10.1128/jcm.30.10.2606-2612.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Graham B. S., Matthews T. J., Belshe R. B., Clements M. L., Dolin R., Wright P. F., Gorse G. J., Schwartz D. H., Keefer M. C., Bolognesi D. P. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis. 1993 Mar;167(3):533–537. doi: 10.1093/infdis/167.3.533. [DOI] [PubMed] [Google Scholar]
  15. Jilg W., Schmidt M., Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis. 1989 Nov;160(5):766–769. doi: 10.1093/infdis/160.5.766. [DOI] [PubMed] [Google Scholar]
  16. Keefer M. C., Bonnez W., Roberts N. J., Jr, Dolin R., Reichman R. C. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis. 1991 Mar;163(3):448–453. doi: 10.1093/infdis/163.3.448. [DOI] [PubMed] [Google Scholar]
  17. Mannhalter J. W., Pum M., Wolf H. M., Küpcü Z., Barrett N., Dorner F., Eder G., Eibl M. M. Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory. AIDS Res Hum Retroviruses. 1991 May;7(5):485–493. doi: 10.1089/aid.1991.7.485. [DOI] [PubMed] [Google Scholar]
  18. Mosier D. E., Gulizia R. J., MacIsaac P. D., Corey L., Greenberg P. D. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2443–2447. doi: 10.1073/pnas.90.6.2443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. SALK J. E. Antigenic potency of poliomyelitis vaccine; influence on degree and duration of vaccine effect. J Am Med Assoc. 1956 Dec 15;162(16):1451–1459. doi: 10.1001/jama.1956.02970330023006. [DOI] [PubMed] [Google Scholar]
  20. SALK J. E. Considerations in the preparation and use of poliomyelitis virus vaccine. J Am Med Assoc. 1955 Aug 6;158(14):1239–1248. doi: 10.1001/jama.1955.02960140001001. [DOI] [PubMed] [Google Scholar]
  21. Schwartz D. H., Gorse G., Clements M. L., Belshe R., Izu A., Duliege A. M., Berman P., Twaddell T., Stablein D., Sposto R. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet. 1993 Jul 10;342(8863):69–73. doi: 10.1016/0140-6736(93)91283-r. [DOI] [PubMed] [Google Scholar]
  22. Skinner M. A., Langlois A. J., McDanal C. B., McDougal J. S., Bolognesi D. P., Matthews T. J. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol. 1988 Nov;62(11):4195–4200. doi: 10.1128/jvi.62.11.4195-4200.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Westblom T. U., Belshe R. B., Gorse G. J., Anderson E. L., Berry C. F. Characteristics of a population volunteering for human immunodeficiency virus immunization. NIAID AIDS Clinical Trials Network. Int J STD AIDS. 1990 Mar;1(2):126–128. doi: 10.1177/095646249000100211. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES